JLJian Liu

Jian Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jian Liu has a total of 244 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ubiquitination-Informed Reinforcement Learning Linker Generator Enables Discovery of Novel FGFR4 PROTAC Degraders

    by Xunkai Yin, Yihui Cai, Shulan Mei, Songyun Xu, Hanyuan Zhang, Xiaoqian Peng, Wenyu Lu, Zhenzhen Zhu, Wenzhuo Xu, Zhe Zheng, et al.

    Proteolysis-targeting chimeras (PROTACs) represent a promising therapeutic strategy, yet rational linker design is limited by inadequate theoretical guidance. Herein, we report PotentialLinker, a novel reinforcement learning framework for PROTAC linker optimization that uses a normalized weighted harmonic mean (NWHM) score to predict degradation activity. Benchmarking on ternary structures confirms its performance without precomputed protein−protein complexes. In case studies of STAT3/RIPK1, it recapitulated structure−activity relationships (SAR) and recommended appropriate E3 ligases. Then, conducted by PotentialLinker, a potent FGFR4 degrader D11 was obtained (DC50 = 56.23 nM, Dmax = 89.58%). Due to its covalent interacting with the unique Cys552 in FGFR4, D11 possesses excellent FGFR4 selectivity. Furthermore, D11 also demonstrated favorable oral bioavailability (F = 21.3%) and potent antitumor efficacy (TGI = 87.07%) with acceptable tolerability in vivo. Taken together, this framework effectively bridges degradation theory and practical PROTAC design, which can be utilized for the rational design of PROTAC-based therapeutic agents.

  • UCEC: A Knowledge Graph-Assisted Machine Learning for Molecular-Mechanism-Interpretable Natural Product-Disease Association Prioritization

    by Wenyu Lu, Yihui Cai, Xiaoqian Peng, Shulan Mei, Xunkai Yin, Zhe Zheng, Zhenzhen Zhu, Songyun Xu, Hanyuan Zhang, Yue Wang, et al.

    Natural products (NPs) have been considered a critical source of therapeutic drugs, but prioritizing NP-disease associations remain challenging because supporting evidence is distributed across multiple ingredients, targets, protein interactions, and pathways. Herein, we propose a knowledge graph-assisted machine learning model: Uncertainty-Calibrated Evidence-Chains (UCEC) for prioritizing NP-disease associations. UCEC separates predicted association strength from the evidence-conditioned stability of local mechanistic support. On a proxy benchmark designed to recover graph-supported indirect associations, evidence-chain integration increased Hits@50 from 0.392 to 0.509, with 68.8% of NPs indicating improved per-NP AUPRC. Source-separated validation using HERB 2.0 clinical trial records further supported candidate prioritization. Thus, UCEC provides a reliability-aware approach for prioritizing graph-supported NP-disease candidates and generating traceable mechanistic hypotheses for subsequent validation.

  • Arglabin targets a non-canonical NLRP3/CCR2 axis to suppress MDSC infiltration and potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma

    by Di Kang, Junyuan Duan, Qi Lv, Yue Wang, Jiayi Meng, Zhenzhen Cui, Yu Sun, Xiying Wang, Weijiang Lin, Xiuzhen Chen, et al.

  • Open Access

    Multimodal AI‐Driven Identification of Dehydrocostus Lactone as a Potent Renal Fibrosis Attenuator Targeting IQGAP1

    by Weijiang Lin, Wenzhuo Xu, Kang Liu, Ping Wang, Zhenzhen Zhu, Wenyu Lu, Zhe Zheng, Xiaoqian Peng, Xunkai Yin, Shulan Mei, et al.

    Renal fibrosis, a hallmark of chronic kidney disease (CKD), remains a critical therapeutic challenge with limited effective interventions. Herein, we proposed a multimodal AI‐driven Traditional Chinese Medicine (TCM) symptom prediction model (TCM‐SPred) and predicted potential herb‐symptom associations between herbs and symptoms to obtain agents for treating renal fibrosis. The prediction results of TCM‐SPred revealed that a natural guaianolide sesquiterpene lactone derivative dehydrocostus lactone (DCL, a main chemical constituent of Aucklandiae Radix) demonstrated significant anti‐fibrotic effects in vivo (unilateral ureteral obstruction) and in vitro (TGF‐β1‐induced epithelial‐mesenchymal transition). DCL directly targeted IQGAP1 to inhibit the Wnt signaling pathway by blocking the interaction between IQGAP1 and CCT3. These findings highlight the potential of DCL as a promising therapeutic candidate for renal fibrosis, providing novel insights into the IQGAP1‐CCT3‐Wnt signaling axis as a potential target for renal fibrosis intervention.


  • Open Access

    Inhibition of DDX5-Mediated G-Quadruplex Unwinding in the β-Catenin 5′-UTR by Magnesium Isoglycyrrhizinate Alleviates Chemotherapy-Induced Intestinal Injury

    by Ying Zhang, Wenqiang Fu, Yaohui Wang, Anyuan Wu, Zhenzhen Zhu, Xunkai Yin, Yan Li, Yongdi Sun, Wenpu Shi, Jianming Cheng, et al.

    Chemotherapy-induced gastrointestinal toxicity, particularly intestinal barrier disruption and diarrhea, is a major dose-limiting adverse effect with unclear mechanisms. Here, we identify magnesium isoglycyrrhizinate (MIG) as a novel therapeutic agent that ameliorates 5-fluorouracil (5-FU)- and irinotecan-induced intestinal injury by enhancing epithelial barrier integrity. Using MIG as a molecular probe, we revealed a pathogenic mechanism underlying chemotherapy-induced barrier damage. Integrated chemoproteomics (limited proteolysis–mass spectrometry and thermal proteome profiling) analyses revealed direct binding of MIG to the RNA helicase DDX5 (DEAD-box helicase 5), whose expression is markedly increased upon 5-FU-induced injury. Mechanistically, DDX5 destabilizes the G-quadruplex (G4) structure in the CTNNB1 (β-catenin) 5′ untranslated region, suppressing β-catenin production and compromising barrier function. Crucially, MIG acts as a novel DDX5 inhibitor that blocks G4 unwinding, thereby restoring β-catenin expression and barrier integrity in a dose-dependent manner. In vivo, MIG outperforms the canonical DDX5 inhibitor supinoxin in mitigating intestinal damage. Taken together, the results of our study not only establish MIG as a promising therapeutic candidate but also delineate the DDX5/ CTNNB1 axis as a targetable pathway for treating chemotherapy-induced barrier dysfunction.

  • Machine Learning-Guided Generation of Novel Pseudo-Natural Products: Applications to Accelerate Drug Discovery

    by Wenyu Lu, Xiaoqian Peng, Yan Huang, Zhe Zheng, Zhenzhen Zhu, Xunkai Yin, Wenzhuo Xu, Shulan Mei, Xiuhong Lu, Xia Zhang, et al.

    Natural products (NPs) are a critical source for drug discovery, and artificial intelligence (AI) is utilized to improve the efficiency of NP-based drug discovery. However, the existing AI-driven models typically generate a library of pseudo-natural products that only covers a small portion of the chemical space and the compounds were also restricted by poor drug-likeness profiles. Herein, the GPT1 is developed to generate diverse pseudo-natural products with excellent validity, uniqueness, and novelty while retaining molecular features similar to the training set. Subsequently, the Augmented Hill-Climb (AHC) strategy is employed to generate synthetically accessible compounds with enhanced drug-likeness. Using the integrated NPDL-GEN model (GPT1 + AHC), compounds G1-G5 were obtained, exhibiting significantly improved drug-likeness profiles. Furthermore, the pseudo-natural products H1-H3 generated via transfer learning also possess potent anti-inflammatory activities. Thus, our developed machine learning models can accelerate NP-based drug discovery.


  • AI-Driven Transfer Learning and Generative Model (TransGenGRU) Enables the Drug Discovery of Novel Natural Guaianolide Sesquiterpene Derivatives as Potent NLRP3 Inhibitors

    by Weijiang Lin, Ping Wang, Yishu Zhang, Wenyu Lu, Meng Yang, Zhenzhen Zhu, Xunkai Yin, Jiahao Lv, Zhe Zheng, Shulan Mei, et al.

    The NLRP3 inflammasome is recognized as a critical mediator of innate immunity, which can regulate the maturation of proinflammatory cytokines. Nowadays, several natural products have been confirmed to exhibit potent NLRP3 inhibitory effects and possess novel binding mechanisms with NLRP3. Herein, an AI-driven model (TransGenGRU) is proposed to generate novel natural products with NLRP3 inhibitory activities. Through the modeling of TransGenGRU, two guaianolide sesquiterpenoids (A3 and A8) are identified to possess moderate NLRP3 inhibitory activities. Then, through detailed structure optimization, E1 demonstrates the most potent NLRP3 inhibitory activity (IC50 = 24.42 nM), and the inhibitory effect on the NLRP3 inflammasome is correlated to the assembly of NLRP3/pro-caspase-1/ASC. Notably, E1 is confirmed to covalent-irreversibly interact with Cys280 that is totally different from MCC950. Besides, E1 also demonstrates potent anti-inflammatory activity in vivo, favorable DMPK profiles, and low hERG toxicity. Thus, E1 has been considered a novel and potent NLRP3 inhibitor.


  • Highly potent and selective degrader targeting ERα to improve the treatment outcomes of breast cancer

    by Xueting Bao, Xunkai Yin, Jinjing Xu, ZhenZhen Zhu, Wenyu Lu, Yihui Cai, Rupeng Dai, Zhe Zheng, Wenzhuo Xu, Shulan Mei, et al.


  • Open Access

    Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3

    by Qi Lv, Yishu Zhang, Juan Wang, Weijiang Lin, Ying Xie, Hongqiong Yang, Xunkai Yin, Zhenzhen Zhu, Yifan Cui, Yang Hu, et al.

    The activation of nucleotide oligomerization domain‐like receptor (NLR) family, pyrin domain‐containing protein 3 (NLRP3) inflammasome is implicated in the pathogenesis of various inflammatory diseases. The natural product oridonin possesses a novel mechanism for NLRP3 inhibition and a unique binding mode with NLRP3, but its poor anti‐inflammatory activity limits further application. After virtual screening of diverse natural product libraries, dehydrocostus lactone (DCL) was considered as a potential NLRP3 inhibitor. DCL effectively inhibited caspase‐1 cleavage and release of IL‐1β in mouse and human macrophages at an extremely low concentration of 10 nM, comparable to MCC950. Mechanistically, our study assigned DCL a novel role in disrupting NLRP3 inflammasome assembly and ASC oligomerization. Excluding the influence on potassium/chloride ion efflux, calcium ion influx, and production of mitochondrial ROS, DCL formed a covalent bond with cysteine 280 in NACHT domain of NLRP3, thereby inhibiting the interaction between NLRP3 and NEK7. Furthermore, DCL exhibited protective effects in mouse models of NLRP3 inflammasome‐mediated diseases, including dextran sulfate sodium‐induced colitis, 2,4,6‐trinitrobenzenesulfonic acid‐induced Crohn's disease, LPS‐induced septic shock, and monosodium urate‐induced peritonitis. Our findings identify NLRP3 as the direct target of DCL, positioning DCL as a promising lead compound for treatment of NLRP3 inflammasome‐related diseases.


  • Stress-induced pro-inflammatory glioblastoma stem cells secrete TNFAIP6 to enhance tumor growth and induce suppressive macrophages

    by Danling Gu, Lang Hu, Kailin Yang, Wei Yuan, Danyang Shan, Jiancheng Gao, Jiahuang Li, Ryan C. Gimple, Deobrat Dixit, Zhe Zhu, et al.